Fusing the targeting molecule to an albumin-binding moiety to increase the size of the construct by noncovalent binding to serum albumin is a useful strategy to extend in vivo half-life, improve the bioavailability, reduce the kidney and liver uptake, and increase the tumor uptake [38,46]. The gene discussed is ALB; the disease is neoplasm.